A 12-year follow-up in sporadic inclusion body myositis: An end stage with major disabilities

Brain

Volumn 134, Issue 11, 2011, Pages 3167-3175

  Cox, Fieke M ^a   Titulaer, Maarten J ^a   Sont, Jacob K ^a   Wintzen, Axel R ^a   Verschuuren, Jan J G M ^a   Badrising, Umesh A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

euthanasia; follow up; inclusion body myositis; life expectancy; muscle strength

Indexed keywords

ADULT; AGED; ARTICLE; DAILY LIFE ACTIVITY; DEATH; DEEP SEDATION; DISEASE COURSE; DISEASE SEVERITY; EUTHANASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; LABORATORY TEST; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MUSCLE EXAMINATION; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SURVIVAL; WHEELCHAIR;

EID: 81055144452     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr217     Document Type: Article

References (30)

1. Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51: 369-72. (Pubitemid 34206293)
2. Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55: 1385-7.
3. Badrising UA, Maat-Schieman ML, van Houwelingen JC, van Doorn PA, van Duinen SG, van Engelen BG, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol 2005; 252: 1448-54. (Pubitemid 41803832)
4. Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, Wintzen AR, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004; 63: 2396-8. (Pubitemid 40024360)
5. Brooke MH. A clinicians view of neuromuscular disorders. Baltimore: Williams and Wilkins; 1986.
6. Cohen R, Lipper S, Dantzker DR. Inclusion body myositis as a cause of respiratory failure. Chest 1993; 104: 975-7. (Pubitemid 23268994)
7. Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. Int Disabil Stud 1991; 13: 50-4.
8. Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol 2009; 256: 2009-13.
9. Dalakas MC. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006; 2: 437-47. (Pubitemid 44137945)
10. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132: 1536-44.
11. Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine 2001; 80: 320-7. (Pubitemid 32879294)
12. Lindberg C, Persson LI, Bjorkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994; 89: 123-31. (Pubitemid 24095268)
13. Mahoney DW, Barthel DW. Functional evaluation; the Barthel index. Md State Med J 1965; 14: 61-5.
14. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620-31. (Pubitemid 46921056)
15. Needham M, James I, Corbett A, Day T, Christiansen F, Phillips B, et al. Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79: 1056-60.
16. Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis. Am J Phys Med Rehabil 2008; 87: 883-9.
17. Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000; 55: 296-8. (Pubitemid 30604636)
18. Personius KE, Pandya S, King WM, Tawil R, McDermott MP. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther 1994; 74: 253-63. (Pubitemid 24067063)
19. Radunovic A, Annane D, Jewitt K, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2009;CD004427.
20. Rose MR, McDermott MP, Thornton CA, Palenski C, Martens WB, Griggs RC. A prospective natural history study of inclusion body myo-sitis: implications for clinical trials. Neurology 2001; 57: 548-50. (Pubitemid 32757615)
21. Sadjadi R, Rose MR. What determines quality of life in inclusion body myositis? J Neurol Neurosurg Psychiatry 2010; 81: 1164-6.
22. Saunders WB. In: Parkinson M, editor. Aids to the examination of the peripheral nervous system. London: Elsevier; 2000. Statistics Netherlands. Statistical yearbook of the Netherlands. December 2010. www@cbs.nl.
23. Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol 1993; 13: 256-63. (Pubitemid 23300092)
24. Teixeira A, Cherin P, Demoule A, Levy-Soussan M, Straus C, Verin E, et al. Diaphragmatic dysfunction in patients with ideopathic inflammatory myopathies. Neuromuscul Disord 2005; 15: 32-9. (Pubitemid 41556630)
25. van der Heide A, Onwuteaka-Philipsen BD, Rurup ML, Buiting HM, van Delden JJ, Hanssen-de Wolf JE, et al. End-of-life practices in the Netherlands under the Euthanasia Act. N Engl J Med 2007; 356: 1957-65. (Pubitemid 46740305)
26. van der Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry 1991; 54: 244-7.
27. Veldink JH, Wokke JH, van der WG, Vianney de Jong JM, van den Berg LH. Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med 2002; 346: 1638-44. (Pubitemid 34755673)
28. Verschuuren JJ, Badrising UA, Wintzen AR, Engelen B, van der Hoeven H, Hoogendijk JE. Inclusion body myositis. In: Emery A, editor. Diagnostic criteria for neuromuscular disorders. London: Royal Society of Medicine Press, European Neuromuscular Center; 1997. p. 81-4.
29. Voermans NC, Vaneker M, Hengstman GJD, ter Laak HJ, Zimmerman C, Schelhaas HJ, et al. Primary respiratory failure in inclusion body myo-sitis. Neurology 2004; 63: 2191.
30. Wintzen AR, Badrising UA, Roos RA, Vielvoye J, Liauw L, Pauwels EK. Dysphagia in ambulant patients with Parkinson's disease: common, not dangerous. Can J Neurol Sci 1994; 21: 53-6. (Pubitemid 24090752)